Results 21 to 30 of about 219,590 (352)

Pembrolizumab induced-C3 glomerulonephritis and RBC cast nephropathy: a case report

BMC Nephrology, 2023
Background Immune checkpoint inhibitors (ICIs) are increasingly being used in the treatment of several cancers. Pembrolizumab is an anti-programmed cell death-1 (anti-PD-1) monoclonal antibody that is approved for the treatment of metastatic non-small ...
Zhi Yang, Huan Xu, Shenju Gou, Hongyan Wu, Zhangxue Hu   +4 more
doaj   +1 more source

Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer.

New England Journal of Medicine, 2023
BACKGROUND Standard first-line chemotherapy for endometrial cancer is paclitaxel plus carboplatin. The benefit of adding pembrolizumab to chemotherapy remains unclear.
R. Eskander, M. Sill, L. Beffa, Richard G. Moore, J. Hope, Fernanda B. Musa, R. Mannel, M. Shahin, G. Cantuaria, E. Girda, C. Mathews, J. Kavecansky, Charles A Leath Iii, L. Gien, E. Hinchcliff, S. Lele, L. Landrum, F. Backes, R. O'Cearbhaill, T. Al baghdadi, E. Hill, P. Thaker, V. John, S. Welch, A. Fader, M. Powell, C. Aghajanian   +26 more
semanticscholar   +1 more source

Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer-Term Follow-Up From the Phase 3 KEYNOTE-240 Trial

Liver Cancer, 2023
Introduction: KEYNOTE-240 showed a favorable benefit/risk profile for pembrolizumab versus placebo in patients with sorafenib-treated advanced hepatocellular carcinoma (HCC); however, prespecified statistical significance criteria for overall survival ...
Philippe Merle, Masatoshi Kudo, Julien Edeline, Mohamed Bouattour, Ann-Lii Cheng, Stephen Lam Chan, Thomas Yau, Marcelo Garrido, Jennifer Knox, Bruno Daniele, Valeriy Breder, Ho Yeong Lim, Sadahisa Ogasawara, Stéphane Cattan, Yee Chao, Abby B. Siegel, Iván Martinez-Forero, Ziwen Wei, Chih-Chin Liu, Richard S. Finn   +19 more
doaj   +1 more source

The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC [PDF]

, 2017
Background: Immune checkpoint inhibitors improve outcomes compared with chemotherapy in lung cancer. Tumor PD-L1 receptor expression is being studied as a predictive biomarker. The objective of this study was to assess the cost-effectiveness and economic
Abdel-Rahman, Aguiar, Borghaei, Brahmer, Calhoun, Chen, Dent, Domingues, Doyle, Ferlay, Goeree, Hanahan, Herbst, Herbst, Huang, Hurvitz, Masters, Matter-walstra, Moro-Sibilot, Nafees, Passiglia, Petitti, Rittmeyer, Siegel, Stokes, Tartari   +25 more
core   +3 more sources

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.

New England Journal of Medicine, 2021
BACKGROUND Lenvatinib in combination with pembrolizumab or everolimus has activity against advanced renal cell carcinoma. The efficacy of these regimens as compared with that of sunitinib is unclear. METHODS In this phase 3 trial, we randomly assigned (
R. Motzer, B. Alekseev, S. Rha, C. Porta, M. Eto, T. Powles, V. Grünwald, Thomas E. Hutson, E. Kopyltsov, M. Méndez-Vidal, V. Kozlov, A. Alyasova, Sung-Hoo Hong, A. Kapoor, Teresa Alonso Gordoa, J. Merchan, E. Winquist, P. Maroto, J. Goh, Miso Kim, H. Gurney, V. Patel, A. Peer, G. Procopio, T. Takagi, B. Melichar, F. Rolland, U. de Giorgi, Shirley S. Wong, J. Bedke, M. Schmidinger, C. Dutcus, Alan D. Smith, L. Dutta, K. Mody, R. Perini, D. Xing, T. Choueiri   +37 more
semanticscholar   +1 more source

Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report

Journal for ImmunoTherapy of Cancer, 2019
Background Pembrolizumab, an anti-programmed cell death-1 protein monoclonal antibody, is effective for patients with advanced non-small-cell lung cancer.
Teppei Sugano, Masahiro Seike, Yoko Funasaka, Mai Yoshida, Ryoko Takayama, Ken Okamura, Asuka Nakanishi, Toru Tanaka, Susumu Takeuchi, Rintaro Noro, Yuji Minegishi, Kaoru Kubota, Hidehisa Saeki, Akihiko Gemma   +13 more
doaj   +1 more source

Single-cell RNA-sequencing reveals predictive features of response to pembrolizumab in Sézary syndrome

OncoImmunology, 2022
The PD-1 inhibitor pembrolizumab is effective in treating Sézary syndrome, a leukemic variant of cutaneous T-cell lymphoma. Our purpose was to investigate the effects of pembrolizumab on healthy and malignant T cells in Sézary syndrome and to discover ...
Tianying Su, George E. Duran, Alexa C. Kwang, Nirasha Ramchurren, Steven P. Fling, Youn H. Kim, Michael S. Khodadoust   +6 more
doaj   +1 more source

Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma. [PDF]

, 2020
PurposeTumors with low frequencies of checkpoint positive tumor-infiltrating lymphocytes (cpTIL) have a low likelihood of response to PD-1 blockade.
Algazi, Alain P, Andtbacka, Robert HI, Arlauckas, Sean P, Ballesteros-Merino, Carmen, Bannavong, Donna, Bhatia, Shailender, Bifulco, Carlos, Browning, Erica, Canton, David A, Daud, Adil I, Fong, Lawrence, Fox, Bernard A, Francisco, Murray, Gargosky, Sharron, Garris, Christopher, Hermiz, Reneta, Le, Mai, Levine, Lauren P, Oglesby, Arielle, Pierce, Robert, Pittet, Mikael J, Rosenblum, Michael D, Tsai, Katy K, Twitty, Christopher G   +23 more
core   +2 more sources

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma

New England Journal of Medicine, 2019
BACKGROUND The combination of pembrolizumab and axitinib showed antitumor activity in a phase 1b trial involving patients with previously untreated advanced renal‐cell carcinoma.
B. Rini, E. Plimack, V. Stus, R. Gafanov, R. Hawkins, D. Nosov, F. Pouliot, B. Alekseev, D. Soulières, B. Melichar, I. Vynnychenko, A. Kryzhanivska, I. Bondarenko, S. Azevedo, D. Borchiellini, C. Szczylik, M. Markus, R. McDermott, J. Bedke, S. Tartas, Yen‐Hwa Chang, S. Tamada, Qiong Shou, R. Perini, Mei Chen, M. Atkins, T. Powles   +26 more
semanticscholar   +1 more source

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.

New England Journal of Medicine, 2022
BACKGROUND The addition of pembrolizumab to neoadjuvant chemotherapy led to a significantly higher percentage of patients with early triple-negative breast cancer having a pathological complete response (defined as no invasive cancer in the breast and ...
P. Schmid, J. Cortés, R. Dent, L. Pusztai, H. McArthur, S. Kümmel, J. Bergh, C. Denkert, Yeon-Hee Park, R. Hui, N. Harbeck, M. Takahashi, M. Untch, P. Fasching, F. Cardoso, J. Andersen, D. Patt, M. Danso, M. Ferreira, M. Mouret-Reynier, S. Im, J. Ahn, M. Gion, S. Baron-Hay, J. Boileau, Yu Ding, K. Tryfonidis, G. Aktan, V. Karantza, J. O’Shaughnessy   +29 more
semanticscholar   +1 more source